BioHarvest Sciences Inc. Common Stock(BHST)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.5
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BHST

11/13/2026: BHST (1-star) is currently NOT-A-BUY. Pass it for now.

BioHarvest Sciences Inc. is a small-cap biotechnology and packaged foods company that utilizes a proprietary botanical synthesis platform to manufacture active plant-based molecules without growing whole plants. The company's main strengths lie in its clinically validated flagship health supplement, VINIA, and its emerging business-to-business CDMO services. Its primary growth story centers on scaling production for high-value fragrance and specialty ingredient partnerships alongside direct-to-consumer expansion. However, the company faces notable financial execution risks, persistent net operating losses, and micro-cap share volatility. The stock is best suited for growth-oriented investors willing to accept high risk in exchange for potential upside from emerging synthetic biology applications.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers rapid top-line scaling driven by innovative cellular agriculture and high-growth CDMO expansion.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp upside price movements driven by positive clinical milestones or new commercial contract announcements.
Value investorWeak fitThe company currently reports net losses and lacks the earnings history required for traditional value metrics.
Dividend investorWeak fitBioHarvest does not pay dividends, retaining all cash to fund business expansion and technology development.
Low-risk investorWeak fitHigh share price volatility and early-stage small-cap operational risks expose investors to substantial downside fluctuations.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall market capitalization and thin trading liquidity frequently result in sharp intraday and multi-week price swings.
Valuation riskMedium / highBecause the company is not yet consistently profitable, valuations depend heavily on forward revenue projections and execution.
Competition risk (synthetic biology and wellness brands)MediumCompetitors ranging from traditional supplement makers to emerging biotech firms contest market share in functional ingredients.
Business qualityMediumProprietary technology gives the firm strong scientific differentiation, but full commercial maturity is still underway.
Dividend incomeLow / noneNo cash dividends are distributed to shareholders.
Execution riskHighSuccess relies heavily on scaling production yields, fulfilling complex CDMO agreements, and achieving targeted operational breakeven.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 34.12M USD
Price to earnings Ratio -
1Y Target Price 9.25
Price to earnings Ratio -
1Y Target Price 9.25
Volume (30-day avg) 25.7K shares
Beta 1.29
52 Weeks Range 1.37 - 7.59
Updated Date 11/15/2026
52 Weeks Range 1.37 - 7.59
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.51

Sector & Industry Intelligence

Sector

Consumer Defensive

Defensive
Sentiment
Correction Expected
Momentum
BUY Breadth Improving
BUY participation
95.0%
Active BUY / eligible
19 / 20
30-Day BUY Count Change
+13
Market state
Correction Expected

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Industry classification is unavailable for this snapshot.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -17.19%
Avg. Invested days 41
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BHST receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
BHST has moderate overall fundamentals (3 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+13.8%) and strong revenue growth (+37.0%) are partially offset by weak cash generation (FCF margin -27.8%), weak profitability (net margin -32.3%).

Financial Health Rating

★★★★★
BHST's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 47.9%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is BHST's strongest growth driver at +37.0% FY2025 versus FY2024 (strong, 5 stars). By comparison, earnings growth (+13.8%, solid) is also solid, while free-cash-flow growth (-0.7%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 7.6% and approximately 85.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 14.77% supports management-shareholder alignment.

Top 5 Institutional Investors

Alyeska Investment Group, L.P. 2.57%
Thompson, Siegel & Walmsley LLC 1.61%
Evercore Wealth Management, LLC 0.95%
True North Advisors LLC 0.83%
Magnus Financial Group LLC 0.40%

Unit Economics (Per $1K Revenue)

★★★★★
BHST generates approximately $593 of gross profit, $-162 of operating income, and $-278 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.69% (Tax Credit)

Quantitative Style Profile

★★★★★
BHST has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Nutraceutical Products (VINIA)Direct-to-consumer and retail sales of plant-derived dietary supplements utilizing red grape cells.Provides steady, recognizable consumer brand revenue through online health and wellness channels.
CDMO Services & Fragrance ProgramsContract development, custom molecule production, and supply agreements for partner companies in fragrance and therapeutics.Offers high-value business-to-business growth catalysts through custom manufacturing contracts.
Geographic Exposure (North America & Israel)Operations spanning R&D facilities in Israel and primary commercial sales execution in North America.Primarily captures consumer demand from Western wellness markets while maintaining lower-cost engineering roots.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 153.85
Enterprise Value 33.59M
Price to Sales(TTM) 0.96
Enterprise Value 33.59M
Price to Sales(TTM) 0.96
Enterprise Value to Revenue 0.95
Enterprise Value to EBITDA -10.25
Shares Outstanding 22.67M
Shares Floating 19.32M
Shares Outstanding 22.67M
Shares Floating 19.32M
Percent Insiders 14.77
Percent Institutions 7.6

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.